Skip to main content
SpringerLink
Log in

Cost considerations in the OTC switch of antifungals for vaginal candidiasis

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fong IW. Clinical and cost considerations in the pharmacotherapy of vulvo-vaginal candidiasis. PharmacoEconomics 1996 Jun; 9(6): 497–505

    Article  PubMed  CAS  Google Scholar 

  2. Taylor CA, Lipsky MS. Physicians’ perceptions of the impact of the reclassification of vaginal antifungal agents. J Fam Pract 1994 Feb; 38(2): 157–60

    PubMed  CAS  Google Scholar 

  3. Tooley PJH. Patient and doctor preferences in the treatment of vaginal candidosis. Practitioner 1985 Jul; 229: 655–60

    PubMed  CAS  Google Scholar 

  4. Schaaf VM, Perez-Stable EJ, Borechardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med 1990; 150: 1929–33

    Article  PubMed  CAS  Google Scholar 

  5. Mitchell S, Bradbeer C. Over the counter treatment for candidiasis: an opportunity to educate [editorial]. BMJ 1992 Jun 27; 304: 1648

    Article  PubMed  CAS  Google Scholar 

  6. Goode MA, Grauer K, Gums JG. Infectious vaginitis: selecting therapy and preventing recurrence. Postgrad Med 1994 Nov 1; 96(6): 85–96

    PubMed  CAS  Google Scholar 

  7. Sobel JD. Treating resistant vaginal infections. Fern Patient 1995 Nov; 20: 32–46

    Google Scholar 

  8. Gable CB, Engelhart L, Sarma S, et al. Mixed vaginal infections — candidiasis and venereal disease — in Medicaid women. J Res Pharm Econ 1993; 5(1): 69–78

    Google Scholar 

  9. OTC fluconazole for vaginal candidiasis launched. Pharm J 1995 Nov 4; 255: 609

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cost considerations in the OTC switch of antifungals for vaginal candidiasis. Drugs Ther. Perspect 8, 14–16 (1996). https://doi.org/10.2165/00042310-199608040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608040-00006

Search

Navigation